291 related articles for article (PubMed ID: 25873122)
21. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
22. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
23. Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection: A case report.
Guayboon T; Chinthammitr Y; Sukpanichnant S; Horthongkham N; Angkasekwinai N
Medicine (Baltimore); 2021 Dec; 100(49):e28077. PubMed ID: 34889256
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
Lurain K; Yarchoan R; Uldrick TS
Hematol Oncol Clin North Am; 2018 Feb; 32(1):75-88. PubMed ID: 29157621
[TBL] [Abstract][Full Text] [Related]
25. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.
Kaga H; Kurahashi H; Kubota A; Hatano Y; Nanjo H; Wakui H; Takahashi N
Int J Hematol; 2022 Jan; 115(1):129-134. PubMed ID: 34591291
[TBL] [Abstract][Full Text] [Related]
26. A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.
Kantarci FE; Eren R; Gündoğan C; Huq GE; Doğu MH; Suyanı E
J Infect Chemother; 2016 Jul; 22(7):483-5. PubMed ID: 26948831
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
[TBL] [Abstract][Full Text] [Related]
29. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
30. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
[TBL] [Abstract][Full Text] [Related]
31. Multicentric Castleman's disease in a Ghanaian adult.
Dei-Adomakoh YA; Segbefia C; Ekem I; Taylor A
Ghana Med J; 2013 Jun; 47(2):92-5. PubMed ID: 23966747
[TBL] [Abstract][Full Text] [Related]
32. Multifocal Castleman disease in pediatrics: case report.
Baserga M; Rosin M; Schoen M; Young G
J Pediatr Hematol Oncol; 2005 Dec; 27(12):666-9. PubMed ID: 16344673
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
34. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
35. EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity.
Shivane A; Pearce A; Khatib N; Smith MEF
Int J Surg Pathol; 2018 Jun; 26(4):338-341. PubMed ID: 29198143
[TBL] [Abstract][Full Text] [Related]
36. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
Reid E; Nooka A; Blackmon J; Lechowicz MJ
Curr Drug Deliv; 2012 Jan; 9(1):41-51. PubMed ID: 22023215
[TBL] [Abstract][Full Text] [Related]
38. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
Rokx C; Rijnders BJ; van Laar JA
Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
[TBL] [Abstract][Full Text] [Related]
39. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
[TBL] [Abstract][Full Text] [Related]
40. Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report.
Anderson S; Sasson SC; Lee FJ; Cooper W; Larsen S; Garsia R
BMC Infect Dis; 2016 Feb; 16():53. PubMed ID: 26831502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
